Gastroenteropancreatic Neuroendocrine Tumors Clinical Trial
Official title:
An Open-label, Micro-dosing Study to Evaluate Safety, Biodistribution, Dosimetry and Preliminary Efficacy of Two Single 68Ga-OPS202 Doses for the Diagnostic Imaging of Somatostatin Receptor-positive Gastro-entero-pancreatic Neuroendocrine Tumors (GEP NET) Using Positron-emission Tomography / Computed Tomography (PET/CT)
The purpose of this study is to assess the safety and tolerability of 68Ga-OPS202 used for the diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP NETs).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02231762 -
Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
|
Phase 2 | |
| Completed |
NCT02730104 -
Community-based Neuroendocrine Tumor (NET) Research Study
|
||
| Completed |
NCT02608203 -
[68 Ga]-DOTANOC PET/CT in GEP-NETs
|
Phase 2/Phase 3 | |
| Completed |
NCT01842165 -
177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
|
Phase 3 | |
| Completed |
NCT02630654 -
Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs
|
||
| Terminated |
NCT02078843 -
Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03043664 -
Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT04524442 -
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
|
Phase 4 | |
| Active, not recruiting |
NCT04711135 -
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
|
Phase 2 |